Login
← Go Back
Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021
Stock Price vs Company Growth
1d
2.1%
1w
0.1%
1m
8.1%
3m
38.6%
6m
65.9%
1y
88.2%
all
6.2%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 410 2.1%
289
424
Company Overview
Sales
554 Cr
Growth: 8.7%
Profit after Tax
120 Cr
Growth: 20.2%
Small Cap
3,301 Cr
P/E: 27.4x
Industry P/E: 35.0x
Fundamentals
Sales (Cr) ₹ 554
Growth 8.7%
EBITDA 31.2%
P/S 6.0x
Dividend 0.2%
P/E 27.4x
Book Value ₹ 2
PEG Ratio 3.1x
ROE 748.0%
P/B N/A
Shareholding Pattern
Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Belongs to (6 Indices) view more
Investors (6)
jyotsana
rajeev4
shivani....
Followers (1)
Pravinra...